Insider Trading February 10, 2026

Bankwell Financial EVP Sells $52,876 in Stock; Company Posts Q4 Beat

CFO Courtney Sacchetti disposed of 1,062 shares while receiving additional granted shares; Bankwell reported EPS and revenue above estimates for Q4 2025

By Nina Shah BWFG
Bankwell Financial EVP Sells $52,876 in Stock; Company Posts Q4 Beat
BWFG

Bankwell Financial Group Executive Vice President and Chief Financial Officer Courtney E. Sacchetti sold 1,062 shares of the company’s common stock on February 9, 2026, for $52,876, while also receiving granted shares the same day. The regional bank reported fourth-quarter 2025 results that surpassed analyst projections on both EPS and revenue, though its stock showed a modest pre-market decline following the release.

Key Points

  • CFO Courtney E. Sacchetti sold 1,062 shares on February 9, 2026, for $52,876 at an average price of $49.79; prices ranged from $49.47 to $50.21.
  • Sacchetti also received 1,994 and 245 granted shares at no cost on the same day.
  • Bankwell reported Q4 2025 EPS of $1.36 versus $1.19 expected and revenue of $30.32 million versus $28.06 million expected; the stock slipped slightly in pre-market trading despite the beats.

Transaction details

On February 9, 2026, Courtney E. Sacchetti, Executive Vice President and Chief Financial Officer of Bankwell Financial Group, executed a sale of 1,062 shares of common stock at an average price of $49.79, resulting in gross proceeds of $52,876. The execution prices within the trade ranged between $49.47 and $50.21. The sale occurred close to the stock's prevailing quote of $49.32.

On that same date, Sacchetti was also the recipient of two grants of Bankwell common stock: 1,994 shares and 245 shares. Those shares were granted at no cost.


Valuation and recent price action

Analysis indicates the regional bank, with a market capitalization of $380.53 million, is trading below its Fair Value. Over the last 12 months the shares have appreciated substantially, delivering a 61.59% total return.

Bankwell's current valuation metrics include a price-to-earnings ratio of 11.21 and a dividend yield of 1.61%. The company has maintained its dividend for 12 consecutive years.


Operational and financial health signals

A pro research report assessing over 1,400 U.S. equities assigns Bankwell an overall financial health rating of "GOOD" and highlights additional strengths identified in the firm's comprehensive research coverage.


Quarterly results

Bankwell reported fourth-quarter 2025 earnings per share of $1.36, exceeding the consensus estimate of $1.19, a surprise of 14.29%. Revenue for the quarter was $30.32 million, topping the projected $28.06 million. These results indicate that the company outperformed analyst expectations on both the bottom line and top line for the quarter.

Despite the upside in earnings and revenue, the stock experienced a slight dip in pre-market trading following the announcement. Market participants and analysts are continuing to monitor the developments.


Context for investors

The insider sale, paired with concurrent grant receipts and the company's quarterly outperformance, presents several signals market participants may weigh when assessing Bankwell's near-term outlook. The sell and grant activity occurred at prices close to the prevailing market quote, while valuation metrics and the research assessment provide additional data points for investors evaluating the regional bank's position.

Risks

  • The stock showed a modest pre-market decline despite Q4 outperformance, indicating possible mixed investor sentiment in the regional banking sector.
  • Insider selling, even when accompanied by grants, may raise questions among shareholders about near-term liquidity or diversification decisions.
  • Valuation analysis suggests the company is trading below its Fair Value, which may reflect differing interpretations of growth prospects or risk among market participants.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026